FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1865453869> ?p ?o ?g. }

• W1865453869 endingPage "3125" @default.
• W1865453869 startingPage "3117" @default.
• W1865453869 abstract "To develop a combination of pegylated liposomal doxorubicin (Doxil; Alza Pharmaceuticals, Palo Alto, CA) and docetaxel (Taxotere; Aventis Pharmaceutical, Parsipanny, NJ) that can be safely used for the treatment of advanced breast cancer.Forty-one patients with locally advanced (n = 10) or metastatic (n = 31) breast cancer received Doxil (30-, 40-, or 45-mg/m(2) intravenous [IV] infusion over 30 to 60 minutes), followed 1 hour later by docetaxel (60 or 75 mg/m(2) by IV infusion over 1 hour) in cohorts of three to six patients. Dose-limiting toxicity (DLT) was defined as febrile neutropenia, prolonged neutropenia, or grade 3 to 4 nonhematologic toxicity that occurred during cycle 1.In conjunction with docetaxel 75 mg/m(2) every 4 weeks, the MTD of Doxil was 30 mg/m(2) and required granulocyte colony-stimulating factor (G-CSF) to prevent febrile neutropenia. Without G-CSF, the MTD was docetaxel 60 mg/m(2) and Doxil 30 mg/m(2) every 3 weeks; only 1 (7%) out of 15 patients treated at this dose level had cycle 1 DLT. Infusion reactions were common with Doxil with the recommended infusion schedule during the first cycle (55%) but were reduced with a modified schedule (7%). There was no clinically significant cardiac toxicity. Objective response occurred in eight of nine assessable patients with stage III disease and in 16 (52%) of 31 patients (95% confidence interval, 34% to 70%) with stage IV disease.The recommended dose and schedule of this combination for further evaluation is Doxil 30 mg/m(2) and docetaxel 60 mg/m(2) given every 3 weeks without G-CSF. When used with G-CSF, it is Doxil 30 mg/m(2) and docetaxel 75 mg/m(2) every 4 weeks." @default.
• W1865453869 created "2016-06-24" @default.
• W1865453869 creator A5011233983 @default.
• W1865453869 creator A5026024346 @default.
• W1865453869 creator A5040980438 @default.
• W1865453869 creator A5083912691 @default.
• W1865453869 creator A5084480086 @default.
• W1865453869 creator A5085875361 @default.
• W1865453869 date "2001-06-15" @default.
• W1865453869 modified "2023-09-26" @default.
• W1865453869 title "Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer" @default.
• W1865453869 cites W1262485082 @default.
• W1865453869 cites W1769308960 @default.
• W1865453869 cites W1804680040 @default.
• W1865453869 cites W1820276215 @default.
• W1865453869 cites W1828224642 @default.
• W1865453869 cites W1918322381 @default.
• W1865453869 cites W1968785826 @default.
• W1865453869 cites W1973473600 @default.
• W1865453869 cites W1974513579 @default.
• W1865453869 cites W1978728063 @default.
• W1865453869 cites W1998346656 @default.
• W1865453869 cites W2000433012 @default.
• W1865453869 cites W2009058800 @default.
• W1865453869 cites W2012879110 @default.
• W1865453869 cites W2019995515 @default.
• W1865453869 cites W2028353414 @default.
• W1865453869 cites W2048564699 @default.
• W1865453869 cites W2056768996 @default.
• W1865453869 cites W2076668534 @default.
• W1865453869 cites W2094027125 @default.
• W1865453869 cites W2095398701 @default.
• W1865453869 cites W2103999755 @default.
• W1865453869 cites W2119597015 @default.
• W1865453869 cites W2148845753 @default.
• W1865453869 cites W2165837635 @default.
• W1865453869 cites W2169253572 @default.
• W1865453869 cites W2318605753 @default.
• W1865453869 cites W4237847727 @default.
• W1865453869 cites W4293241248 @default.
• W1865453869 doi "https://doi.org/10.1200/jco.2001.19.12.3117" @default.
• W1865453869 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11408509" @default.
• W1865453869 hasPublicationYear "2001" @default.
• W1865453869 type Work @default.
• W1865453869 sameAs 1865453869 @default.
• W1865453869 citedByCount "71" @default.
• W1865453869 countsByYear W18654538692013 @default.
• W1865453869 countsByYear W18654538692014 @default.
• W1865453869 countsByYear W18654538692015 @default.
• W1865453869 countsByYear W18654538692016 @default.
• W1865453869 countsByYear W18654538692017 @default.
• W1865453869 countsByYear W18654538692019 @default.
• W1865453869 countsByYear W18654538692021 @default.
• W1865453869 countsByYear W18654538692022 @default.
• W1865453869 countsByYear W18654538692023 @default.
• W1865453869 crossrefType "journal-article" @default.
• W1865453869 hasAuthorship W1865453869A5011233983 @default.
• W1865453869 hasAuthorship W1865453869A5026024346 @default.
• W1865453869 hasAuthorship W1865453869A5040980438 @default.
• W1865453869 hasAuthorship W1865453869A5083912691 @default.
• W1865453869 hasAuthorship W1865453869A5084480086 @default.
• W1865453869 hasAuthorship W1865453869A5085875361 @default.
• W1865453869 hasConcept C121608353 @default.
• W1865453869 hasConcept C126322002 @default.
• W1865453869 hasConcept C141071460 @default.
• W1865453869 hasConcept C2775930923 @default.
• W1865453869 hasConcept C2776694085 @default.
• W1865453869 hasConcept C2777063308 @default.
• W1865453869 hasConcept C2778850193 @default.
• W1865453869 hasConcept C2781190966 @default.
• W1865453869 hasConcept C29730261 @default.
• W1865453869 hasConcept C530470458 @default.
• W1865453869 hasConcept C71924100 @default.
• W1865453869 hasConcept C90924648 @default.
• W1865453869 hasConceptScore W1865453869C121608353 @default.
• W1865453869 hasConceptScore W1865453869C126322002 @default.
• W1865453869 hasConceptScore W1865453869C141071460 @default.
• W1865453869 hasConceptScore W1865453869C2775930923 @default.
• W1865453869 hasConceptScore W1865453869C2776694085 @default.
• W1865453869 hasConceptScore W1865453869C2777063308 @default.
• W1865453869 hasConceptScore W1865453869C2778850193 @default.
• W1865453869 hasConceptScore W1865453869C2781190966 @default.
• W1865453869 hasConceptScore W1865453869C29730261 @default.
• W1865453869 hasConceptScore W1865453869C530470458 @default.
• W1865453869 hasConceptScore W1865453869C71924100 @default.
• W1865453869 hasConceptScore W1865453869C90924648 @default.
• W1865453869 hasIssue "12" @default.
• W1865453869 hasLocation W18654538691 @default.
• W1865453869 hasLocation W18654538692 @default.
• W1865453869 hasOpenAccess W1865453869 @default.
• W1865453869 hasPrimaryLocation W18654538691 @default.
• W1865453869 hasRelatedWork W1867786113 @default.
• W1865453869 hasRelatedWork W1975239262 @default.
• W1865453869 hasRelatedWork W2004842027 @default.
• W1865453869 hasRelatedWork W2030335662 @default.
• W1865453869 hasRelatedWork W2096955328 @default.
• W1865453869 hasRelatedWork W2103792825 @default.
• W1865453869 hasRelatedWork W2106964779 @default.

• next